但是正如诺和诺德所言，司美格鲁肽无论是减肥版还是降糖版都面临激烈竞争。一方面受到礼来替尔泊肽等同类创新药的强势追击，另一方面受到非法仿制药的市场挤压，销售额增速并未如预期般高歌猛进。

BEIJING, July 31 (Xinhua) -- China's manufacturing sector softened slightly in July due to seasonal factors, but underlying growth momentum remained resilient, with emerging industries gaining ...

但市场反应远比财务数据更激烈，诺和诺德当日美股股价跌幅最高24%。更重要的是，投资者不再把它视为GLP-1减肥药的无可争议领跑者。过去一年，诺和诺德股价已累计暴跌逾58%。

BEIJING, July 31 (Xinhua) -- China's manufacturing sector softened slightly in July due to seasonal factors, but underlying growth momentum remained resilient, with emerging industries gaining ...

In her view, affordability remains the shared bottleneck for both developed and emerging economies, compounded by gaps in capacity-building, knowledge, and skills. To accelerate green and zero-carbon ...

GLP-1RA短缺催生的复合制剂市场存在严重信息不对称问题。耶鲁大学团队通过79家网站调查发现，50%未标注不良反应，40%宣称未经FDA批准的疗效（如神经保护）。研究呼吁临床医生主动开展基于循证指南（如ADA声明）的 compassionate conversation（共情对话），在监管缺位环境下保护患者免受误导性广告（如2025超级碗广告）影响。